Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trialJonas Bergh, Nils Wilking, Tom Wiklund et al.|The Lancet|2000Cited by 343
Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifenJohan Rosell, John Carstensen, Tommy� Fornander et al.|Acta Oncologica|2017Cited by 32
Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-upJohan Rosell, John Carstensen, Bo Nordenskjöld et al.|Breast Cancer Research and Treatment|2013Cited by 30
A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancerSara Margolin, Nils‐Olof Bengtsson, Lena Carlsson et al.|Acta Oncologica|2010Cited by 19
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER TrialAlexios Matikas, I. Thalmann, Volker Möbus et al.|Journal of Clinical Oncology|2024Cited by 11